Completion of the procedure No. 53/2020-SARCO without selection of the winner tender

On November 5, 2020, the Ordering Party has signed an exclusive license agreement with Galapagos NV for the global development and commercialization rights of OATD-01 for the treatment of idiopathic pulmonary fibrosis (IPF) and other diseases with a fibrotic component. According to the provisions of this agreement, as of Nov 5, Galapagos has taken over the responsibility for further development of OATD-01. Therefore, the Ordering Party pursuant to the provisions of point III.3 of the Request for proposal No. 53/2020–SARCO completes the procedure without choosing the winner tender.